|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reteplase#Contraindications]] |
| {{Reteplase}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Contraindications==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations
| | [[Category: Anticoagulants]] |
| | |
| *'''Active internal [[bleeding]]'''
| |
| | |
| *'''History of [[cerebrovascular accident]]'''
| |
| | |
| *'''Recent intracranial or intraspinal surgery or trauma (see [[Reteplase warnings and precautions|WARNINGS]])'''
| |
| | |
| *'''Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]]'''
| |
| | |
| *'''Known bleeding [[diathesis]]'''
| |
| | |
| *'''Severe uncontrolled [[hypertension]]'''<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |